READING TIME TOPIC 24

linxingxing

3 @: T4 n2 N. r) A/ x
: p& F- y0 E! p' B  p$ U% QToday' s topic: Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy+ \- C. h! \/ Z9 q5 }; N

% y. W# F: v+ D' qThe summary and the paper is in the attachments.5 {6 b2 I! D( E2 |7 I3 D+ A
1 you could try to translate the summary
! {+ F5 D1 P5 [4 I9 D) F9 G; E2 you could talk about the author or the institute
" t  k2 p0 H. E3 you could summarize steps of the experiment or the results
! b1 k8 N. |2 F7 r5 c& R$ r! b4 you could give your doubts of this paper2 S+ R: P# ]; [
5 you could upload your record of the summarize
, W$ X+ g8 u! D7 n
$ R: u3 X+ W6 J' |, y! g. P: _If you want to talk something else, please let me know.

linxingxing

- w! c" {  z% c) A" l3 q% t2 D* s: Y3 I9 j8 _# b8 X# Q( b

linxingxing

Luigi Naldini+ y6 D$ J% j4 W/ K1 T
Gene Transfer Technologies and new Gene Therapy Strategies1 d# o; Z  W* I. F, p+ z2 F* d
luigi.naldini@hsr.it
  n& L% e' c9 }9 b: o7 ]# ~6 g9 R, o
9 q/ l5 q9 B; C. R$ K% s5 Y0 f! g, n% f* G2 U5 ?; Q
Somatic gene therapy requires the efficient delivery and sustained expression of therapeutic genes into the tissues of a human body. Such an approach has tremendous therapeutic potential for several inherited and acquired diseases. However, several challenges must be met to fulfill these expectations, starting from the development of more efficient, safe and versatile gene transfer tools.

linxingxing

introduction4 d: _2 n( n+ b
design of lentiviral vectors: D  {4 d$ M$ x
transgen expression by lentiviral vectors
7 J: V  a' _- S8 I/ x  Abiosafty of lentiviral vectors1 T& {3 ~- B1 S& N( W3 [9 D
non-primate lentiviral vectors& w; q3 }" r/ n7 d
gene transfer performance  W: R! n0 c3 Z( V. u3 o% s, _
conclusions and perspectives7 F) ]! D  g$ H1 D( y
reference

linxingxing

introduction: H) k/ G# ]3 d
design of lentiviral vectors
: r: s( b9 S4 Vtransgen expression by lentiviral vectors- y0 A, }& X$ a7 i
biosafty of lentiviral vectors+ v- o4 _$ L. g  W- p8 ^5 Q
non-primate lentiviral vectors" S( X9 S, x2 W6 e& O# O+ U3 _
gene transfer performance# R/ G$ T( K; J. f1 T7 b
conclusions and perspectives
; z5 k9 K0 a/ m( ?* g6 |8 C3 dreference

linxingxing

摘要$ v2 X& f( G$ U4 Y" \+ b0 P
来自于慢病毒的慢病毒载体是转基因实验的工具。慢病毒载体从首次应用到现在，已经在设计，生物安全，在目的细胞中转基因表达能力上有了很大改进。目前可用的灵长类和非灵长类慢病毒载体，应用这两种系统在大量组织中的表达的研究在不断向前推进。这里我们回顾在基因治疗方面潜力的慢病毒体系。

linxingxing

QUSETION:
; v7 }- q  M% e* z! }' B1 What' s the differences between primate lentiviral vector and nonprimate  lentiviral vector?what are they?
2 |9 {2 i: ^( a9 A; ]; |* j; {7 ?2 shall we use lentiviral vector in vivo?

linxingxing

please join in actively, you can learn a lot.

linxingxing

"HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa, while HIV-2 viruses are related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Group M can be further subdivided into subtypes based on genetic sequence data. Some of the subtypes are known to be more virulent or are resistant to different medications. Likewise, HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses, although HIV-2 is known to cause AIDS."4 ^1 L$ }) b0 S6 _0 y$ D1 e2 U
  [  N3 K7 p+ r! |$ r/ Y
so primate and nonprimate lentiviral vector are different origins. they used for different hosts.